The stock may react positively to revenue growth and AI/FDA momentum, but traders should monitor whether rising R&D spend translates into near-term commercialization. The recent $14M financing alleviates near-term liquidity concerns, but path to profitability remains distant.
Price Chart
Executive Summary
CapsoVision reported Q4 and full-year 2025 earnings with revenue growth of 13% and 15% respectively, driven by increased capsule sales. Despite top-line growth, the company widened its net loss to $25.3M from $19.9M in 2024 due to higher R&D and public company expenses. It bolstered its cash position with a $14M private placement in March 2026, following its July 2025 IPO which generated $23.4M in net proceeds.
Key Financial Metrics
Key Facts
- Q4 2025 revenue: $3.9M (+13% YoY), full-year 2025 revenue: $13.6M (+15% YoY)
- Gross margin held at 50% in Q4, full-year 2025 margin was 53% (down from 54% in 2024)
- Operating expenses rose to $32.7M in 2025 (+25% YoY), driven by R&D under Canon partnership and public company costs
- Net loss widened to $25.3M in 2025 from $19.9M in 2024; EPS was -$1.03 vs. -$9.85 (outstanding shares increased due to IPO)
- Cash and equivalents: $10.1M as of Dec 31, 2025; $14M private placement completed March 16, 2026
- Submitted 510(k) for AI-assisted module for CapsoCam Plus; advancing next-gen colon and pancreas capsule programs
Financial Impact
Revenue increased by $1.8M year-over-year, but operating losses expanded by $5.6M. Cash runway extended by $14M private placement post-year-end.
Risk Factors
- Continuing operating losses and negative cash flow from operations ($22.9M used in 2025)
- Heavy reliance on future regulatory approvals (FDA 510(k) for AI module not yet cleared)
- Dilution risk from future financings given current burn rate and limited cash
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3263416 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 28, 2026 28d ago | 8-K | $6.92 | awaiting T+60 | — | $6.89 (−0.43%) |
Sep 28, 2026 28d ago | Press Release | $6.92 | awaiting T+60 | — | $6.89 (−0.43%) |
Sep 23, 2026 4w ago | Insider Cluster | $6.17 | awaiting T+60 | — | $6.89 (+11.67%) |
Sep 22, 2026 4w ago | Institutional Cluster | $6.30 | awaiting T+60 | — | $6.89 (+9.37%) |
Sep 18, 2026 5w ago | 424B5 | $6.70 | awaiting T+60 | — | $6.89 (−2.84%) |
Aug 24, 2026 9w ago | EFFECT | $5.83 | awaiting T+60 | — | $6.89 (−18.18%) |
Aug 13, 2026 10w ago | S-3 | $6.46 | awaiting T+60 | — | $6.89 (−6.66%) |
Jul 21, 2026 13w ago | Insider Buy | $6.91 $6.45 | ▼ −6.66% | ▼ −9.92% | $6.89 (−0.29%) |
Jul 10, 2026 15w ago | Insider Buy | $6.22 $6.50 | ▲ +4.50% | ▲ +0.51% | $6.89 (+10.77%) |
Jul 7, 2026 15w ago | Insider Buy | $6.13 $6.32 | ▲ +3.18% | ▲ +0.69% | $6.89 (+12.49%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers